Search PubMed⌕ Search

Biomedical subjects

Kiat Tsong Tan

Publications and source records attributed to Kiat Tsong Tan.

4 recordsLinked to original sources
PubMed2006

CT vs conventional angiography in unselected patients with suspected coronary heart disease.

BACKGROUND: To provide confirmatory evidence that the accuracy of MSCT coronary angiography is comparable to that of conventional coronary angiography. METHOD: 19 patients who had both MSCT and conventional coronary angiography were included in our study. The mean age of our patients was 62.3 (SD 7.7) and 42% of our patients were female. The coronary vascular tree was subdivided into 13 segments (modified from the 16-segment AHA classification). The grade of disease was classified into 1 of 6 categories; (1)0-50% stenosis; (2) 50-75% stenosis; (3) 75-99% stenosis; (4) Occluded; (5) aneurysmal; (6) fistula. The results of the imaging studies were analysed by two radiologists, who were blinded to the clinical data. RESULTS: A total of 172 coronary artery segments were visualised on both CT and conventional angiography. There is excellent statistical correlation between the appearance of the coronary arteries on MSCT and conventional angiography, as determined by Spearmans test (r=0.727, P<0.0001). MSCT coronary angiography had a sensitivity of 80.0%, specificity of 95.9%, NPV of 97.9% and PPV of 66.7%. CONCLUSION: The specificity and NPV from our study are similar to those obtained by previous researchers. This study confirms that a negative CT coronary angiogram is useful to rule out the presence of significant coronary heart disease.

Coronary Angiography↗
PubMed2003

Platelets, atherosclerosis and the endothelium: new therapeutic targets?

One of the major causes of morbidity and mortality in the developed world is atherosclerosis. Recent research has suggested that the interaction of platelets with the endothelium is important in both the progression of atherosclerosis and the development of the acute complications of the disease. Both of these cells secrete various signalling molecules and express adhesion molecules, which can influence the development of pathological states. Certainly, there may be a vicious cycle in which platelet activation promotes atherosclerosis; a process involving inflammation and the activation of many other cell types (for example, leukocytes and smooth muscle cells), which causes further platelet activation. Therefore, intense effort has been made to develop therapeutic agents that can modulate the function of these cells, with the ultimate aim to retard (or even reverse) the progression of atheroma growth.

Arteriosclerosis↗
PubMed2003

Factor X inhibitors.

Factor X plays a central role in coagulation, being the point of convergence of the extrinsic and intrinsic pathways of blood clotting. It may also act as one of the links between the coagulation and inflammatory pathways. These findings suggest that factor X may represent an attractive target for a new antithrombotic drug. Indeed, a factor X inhibitor, fondaparinux, has already been approved for clinical use to prevent post-operative deep vein thrombosis. Factor X inhibitors are also being evaluated for use in the treatment of the acute coronary syndromes, pulmonary embolism and deep vein thrombosis. Oral factor X inhibitors are also being developed, which may be of use in the outpatient prevention and/or treatment of stroke and thromboembolism.

Anticoagulants↗